Drug makers might be deterred from making the heavy investment in researching an Alzheimer's use for bexarotene.
WSJ: Alzheimer's Families Clamor for Drug
2.
Ms. Vear wants to try her father on bexarotene, though she does have concerns about possible side effects.
WSJ: Alzheimer's Families Clamor for Drug
3.
Patents on bexarotene will start to expire this year, and once a generic is available, doctors could prescribe that less-expensive version off-label, undercutting the commercial prospects.